Clinical Trials
23 trialsNCT02115282 2026-05-29
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03199885 2026-05-29
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT04588246 2026-05-20
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Phase 3 Terminated
NCT03941730 2026-05-12
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT02498613 2026-05-01
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02226276 2026-02-13
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT04692103 2026-01-22
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
Phase 2 Active not recruiting
NCT01093612 2025-11-14
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT02293954 2025-11-14
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
Phase NA Active not recruiting
NCT02827877 2025-11-14
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01149083 2025-08-15
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01937117 2025-07-01
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT00618657 2024-02-28
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
University of California, Irvine
Phase 2 Completed
NCT03831711 2023-12-13
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Stanford University
Phase 1/2 Completed
NCT01719562 2023-05-19
MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum
Wake Forest University Health Sciences
Phase NA Completed
NCT02149173 2021-06-30
F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy
University of Washington
Phase NA Terminated
NCT00602043 2020-02-19
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01720602 2020-01-07
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
University of Washington
Phase NA Completed
NCT01153672 2019-09-06
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
University of Washington
Phase NA Completed
NCT00058058 2019-07-16
ACRIN-6667
American College of Radiology Imaging Network
Phase NA Completed
NCT01928186 2018-05-15
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
University of Washington
Phase NA Completed
NCT00379197 2017-12-28
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00572728 2016-12-30
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed